Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial
- 1 January 1999
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 353 (9150) , 345-350
- https://doi.org/10.1016/s0140-6736(98)07186-4
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer.Journal of Clinical Oncology, 1997
- Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial.Journal of Clinical Oncology, 1993
- Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.Journal of Clinical Oncology, 1990
- Adjuvant Therapy for Patients With Colon and Rectal CancerJAMA, 1990
- Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon CarcinomaNew England Journal of Medicine, 1990
- Prospectively randomized trial of adjuvant active‐specific immunotherapy for human colorectal cancerCancer, 1985
- Active Specific Immunotherapy of Established Micrometastasis: Effect of Cryopreservation Procedures on Tumor Cell Immunogenicity in Guinea Pigs23JNCI Journal of the National Cancer Institute, 1980
- Active specific immunotherapy of residual micrometastasisCancer Immunology, Immunotherapy, 1979
- Specific immunotherapy of established visceral micrometastases by BCG-tumor cell vaccine alone or as an adjunct to surgeryCancer, 1978
- Efficacy of adjuvant fluorouracil and folinic acid in colon cancer: International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigatorsPublished by Elsevier